Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU5GKC)

• Drug Name: Carboxamide derivative 4 Drug Info
• Synonyms: PMID27646564-Compound-11-V
• Cross-matching ID: TTD Drug ID: DMU5GKC

Molecule-Related Drug Atlas

Drug(s) Targeting ALK tyrosine kinase receptor (ALK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[2]
Lorlatinib	DMICDLV	Non-small-cell lung cancer	2C25.Y	Approved	[3]
Entrectinib	DMMPTLH	Non-small cell lung cancer	2C25	Approved	[4]
Brigatinib	DM7W94S	Anaplastic large cell lymphoma	2A90.A	Approved	[5]
Ceritinib	DMB920Z	Non-small-cell lung cancer	2C25.Y	Approved	[6]
Alectinib	DMP1I6Y	Lung cancer	2C25.0	Approved	[7]
Ensartinib	DMIKDCQ	Non-small-cell lung cancer	2C25.Y	Phase 3	[8]
PF-06463922	DMKM7EW	Non-small-cell lung cancer	2C25.Y	Phase 2	[9]
AP26113	DMYBQEF	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
TPX-0005	DM9FB2T	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]

Drug(s) Targeting Proto-oncogene c-Ret (RET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[11]
Regorafenib	DMHSY1I	Metastatic colorectal cancer	2B91	Approved	[2]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[12]
Selpercatinib	DMZR15V	Non-small-cell lung cancer	2C25.Y	Approved	[13]
Pralsetinib	DMWU0I2	Non-small-cell lung cancer	2C25.Y	Approved	[14]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[15]
CEP-32496	DMAO04B	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[16]
GSK3179106	DM2KCIP	Inflammatory bowel disease	DD72	Phase 1	[17]

Drug(s) Targeting Proto-oncogene c-Ros (ROS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[2]
Lorlatinib	DMICDLV	Non-small-cell lung cancer	2C25.Y	Approved	[3]
Entrectinib	DMMPTLH	Non-small cell lung cancer	2C25	Approved	[4]
AB-106	DMEW62S	Non-small cell lung cancer	2C25	Phase 2	[18]
TPX-0005	DM9FB2T	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]
DS-6051	DM0RD4F	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
Imidazo[1,2-b]pyridazine derivative 2	DM1JYNW	Solid tumour/cancer	2A00-2F9Z	Patented	[20]
Imidazo[1,2-b]pyridazine derivative 3	DMPDTG0	Solid tumour/cancer	2A00-2F9Z	Patented	[20]
PMID28270010-Compound-Figure21-b	DM6IYAT	Brain metastases	2D50	Patented	[20]
Imidazo[1,2-b]pyridazine derivative 1	DMULTAI	Solid tumour/cancer	2A00-2F9Z	Patented	[20]

Drug(s) Targeting Fms-like tyrosine kinase 3 (FLT-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[21]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[22]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[12]
Gilteritinib	DMWQ4MZ	Acute myeloid leukaemia	2A60	Approved	[3]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[23]
Lestaurtinib	DMQ2AIJ	Acute myeloid leukaemia	2A60	Approved (orphan drug)	[24]
Pacritinib	DM1T6ZN	Myelofibrosis	2A20.2	Phase 3	[21]
AC220	DM8Y4JS	Acute myeloid leukaemia	2A60	Phase 3	[8]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[25]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ALK tyrosine kinase receptor (ALK)	TTPMQSO	ALK_HUMAN	Inhibitor	[1]
Fms-like tyrosine kinase 3 (FLT-3)	TTGJCWZ	FLT3_HUMAN	Inhibitor	[1]
Proto-oncogene c-Ret (RET)	TT4DXQT	RET_HUMAN	Inhibitor	[1]
Proto-oncogene c-Ros (ROS1)	TTSZ6Y3	ROS1_HUMAN	Inhibitor	[1]

References

• [1] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397).
• [7] CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679-90.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul 13;28(1):70-81.
• [10] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [11] Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
• [12] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
• [16] Clinical pipeline report, company report or official report of Turning Point Therapeutics.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] Clinical pipeline report, company report or official report of AnHeart Therapeutics.
• [19] National Cancer Institute Drug Dictionary (drug id 766123).
• [20] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [21] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
• [22] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [23] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [24] Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
• [25] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.